Actonel Prescription Saver Card
Patients only need to pay the first $20 each month, and the rest is covered, up to $30, which can add up to an annual savings of $360.
The Actonel Prescription Saver Card provides instant, point-of-sale savings each time patients get their prescription for Actonel filled at the pharmacy.
Actonel Mail-in Rebate
Helps patients get up to $20 back each month, with an annual savings of up to $240.
The Actonel rebate is a mail-in program that eligible patients can use after filling their prescription for Actonel each month.
Ask your Actonel sales representative for more information about these money-saving options.
Saver card and rebate are void where prohibited by law. Offers not valid for prescriptions reimbursed or paid under Medicare, Medicaid, or any federal- or state-funded benefit programs. See saver card or rebate for further restrictions. Offers expire 12/31/09.
Actonel is indicated for the treatment of postmenopausal osteoporosis.
Actonel 5 mg and 35 mg are indicated for the prevention of postmenopausal osteoporosis.
Actonel 150 mg may be considered for use for prevention of postmenopausal osteoporosis.
Selected Safety Information for Actonel
Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least
30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).
Bisphosphonates, including Actonel, may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcers. Actonel should be taken according to the dosing instructions to minimize the risk of these events. Patients should discontinue use if new or worsening symptoms occur. There have also been reports of severe and occasionally incapacitating bone, joint and/or muscle pain in patients taking bisphosphonates.
Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Actonel. Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan (including the consideration of discontinuation of bisphosphonate therapy) of each patient based on individual benefit/risk assessment.
Most common adverse reactions reported in >10% of patients treated with Actonel and with a higher frequency than placebo are: back pain, arthralgia, abdominal pain, and dyspepsia. Hypersensitivity reactions (angioedema, generalized rash, bullous skin reactions), and eye inflammation (iritis, uveitis) have been reported rarely.
Please click for Full Prescribing Information for Actonel.
This material is provided in Adobe Acrobat PDF format. If you don't have Acrobat Reader, you can download it by clicking below.
